Literature DB >> 879751

Uniform susceptibility of various strains of Coccidioides immitis to amphotericin B.

M S Collins, D Pappagianis.   

Abstract

The susceptibility of 12 strains of Coccidioides immitis to amphotericin B (amB) was studied in vitro and in vivo. The minimal inhibitory concentration (MIC) of the mycelial phase of these strains was 0.078 to 0.16 mug/ml after 3 days of incubation, but by 15 days all strains were inhibited by 2.5 mug/ml. Mice infected intraperitoneally with these strains were sucessfully treated with 0.5 mg of amB per kg per day. These strains included several studied by others and which reportedly varied widely in susceptibility (MIC from 0.24 to 24.01 mug/ml) to amB. Four of these strains representing this putative broad range of susceptibility were used to infect mice intranasally. Regardless of infecting strain, mice were sucessfully treated with 0.38, 0.75, and 1.5 mg/kg, but 0.19 mg/kg was only partially effective. Thus, in vivo as well as in vitro there was a uniform response of C. immitis strains to amB.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 879751      PMCID: PMC352127          DOI: 10.1128/AAC.11.6.1049

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  The use of amphotericin B in the treatment of coccidioidal disease.

Authors:  W A WINN
Journal:  Am J Med       Date:  1959-10       Impact factor: 4.965

2.  Experience with amphotericin B for the treatment of systemic mycoses.

Authors:  J H SEABURY; H E DASCOMB
Journal:  AMA Arch Intern Med       Date:  1958-12

3.  Experience with amphotericin B.

Authors:  J H SEABURY; H E DASCOMB
Journal:  Ann N Y Acad Sci       Date:  1960-08-27       Impact factor: 5.691

4.  Immunization of mice with viable Cocidioides immitis.

Authors:  D PAPPAGIANIS; H B LEVINE; C E SMITH; R J BERMAN; G S KOBAYASHI
Journal:  J Immunol       Date:  1961-01       Impact factor: 5.422

5.  Approaches to the physiology of Coccidioides immitis.

Authors:  D PAPPAGIANIS; G S KOBAYASHI
Journal:  Ann N Y Acad Sci       Date:  1960-08-27       Impact factor: 5.691

6.  The determination of serum concentrations of amphotericin B in man.

Authors:  R L TAYLOR; H P LYNCH; R R TAYLOR; O L WEISER
Journal:  Am Rev Tuberc       Date:  1958-06

7.  Coccidioidomycosis and its treatment with amphotericin B.

Authors:  M L LITTMAN; P L HOROWITZ; J G SWADEY
Journal:  Am J Med       Date:  1958-04       Impact factor: 4.965

8.  Some aspects of the absorption, distribution, and excretion of amphotericin B in man.

Authors:  D B LOURIA
Journal:  Antibiotic Med Clin Ther (New York)       Date:  1958-05

9.  A therapeutic dilemma. The treatment of disseminated coccidioidomycosis with amphotericin B.

Authors:  W G SANFORD; J R RASCH; R B STONEHILL
Journal:  Ann Intern Med       Date:  1962-04       Impact factor: 25.391

10.  Treatment of disseminated mycotic infectioons. A new approach to amphotericin B therapy.

Authors:  D J Drutz; A Spickard; D E Rogers; M G Koenig
Journal:  Am J Med       Date:  1968-09       Impact factor: 4.965

View more
  4 in total

1.  Traveller's coccidioidomycosis: case report of pulmonary infection diagnosed in Israel.

Authors:  E Lefler; D Weiler-Ravell; D Merzbach; O Ben-Izhak; L A Best
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

2.  Microtiter method for MIC testing with spherule-endospore-phase Coccidioides immitis.

Authors:  R F Hector; B L Zimmer; D Pappagianis
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

3.  Comparative susceptibility of four kinds of pathogenic fungi to amphotericin B and amphotericin B methyl ester.

Authors:  A C Huston; P D Hoeprich
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

4.  Amphotericin B in the treatment of coccidioidomycosis.

Authors:  D J Drutz
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.